Volume : 08, Issue : 05, May – 2021
Title:
22.FORMULATION AND IN VITRO/ INVIVO EVALUATION OF CHRONOMODULATED DRUG DELIVERY OF BARICITINIB
Authors :
Mayuri Bodige, B. Agaiah Goud, M. Bhagavan Raju
Abstract :
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic joint inflammation which ultimately leads to severe disability and premature mortality. It has a global prevalence of around 1% with the incidence among women being 2–3 times more than in men. The pathogenesis of the disease involves preclinical RA, genetic factors, and environmental factors. The RA has no known cure and the primary aim of treatment remains to attain lowest possible disease activity and recovery if possible. The aim of the present investigation was to formulate and evaluate chronomodulated drug delivery system of Baricitinib such that it releases the drug early in the morning, during which the symptoms of rheumatoid arthritis worsen. To develop chronomodulated drug delivery system of Baricitinib, initially core tablets of Baricitinib were prepared using three different supradisintegrants followed by coating with pH dependent polymer of Eudragit S100. The prepared core tablets are evaluated for physical parameters and an optimal system was identified. Further, coating composition of Eudragit L-100 was optimized and coating tablets of Baricitinib was prepared. The prepared coated tablets were evaluated for the in vitro release studies in 0.1N HCl, pH 6.8 phosphate buffer and pH 7.4 phosphate buffer. Formulation with 12.5% of coating solution had shown a significant drug release after a lag time of 3 h (in pH 6.8 medium), 6 h (in pH 6.8 medium) and 8 h (in pH 7.4 medium), respectively. Thus, chronomodulated drug delivery system of Baricitinib was formulated and that if a tablet is administered around 9 pm to 10 pm, the drug release starts after a lag time of 6 h i. e., around 3am to 4 am.
Keywords: Baricitinib, chronomodulated, supradisintegrants
Cite This Article:
Please cite this article in press Mayuri Bodige et al., Formulation And In Vitro/ In vivo Evaluation Of Chronomodulated Drug Delivery Of Baricitinib.., Indo Am. J. P. Sci, 2021; 08(05).
Number of Downloads : 10
References:
1. Janugade BU, Patil SS, Patil SV, Lade PD. Pulsatile drug delivery system for chronopharmacological disorders: an overview. Journal of pharmacy research 2009; 2 (1): 132-143.
2. Parmar RD, Parikh RK, Vidyasagar G, Patel DV, Patel CJ and Patel BD. Pulsatile Drug Delivery Systems: An Overview. International Journal of Pharmaceutical Sciences and Nanotechnology 2009; 2(3): 605.
3. Nitin Saigal, Sanjula Baboota, Alka Ahuja and Javed Ali. Site Specific Chronotherapeutic Drug Delivery Systems: A Patent Review. Recent Patents on Drug Delivery & Formulation 2009; 3: 64-70.
4. Jha N, Bapat S. Chronobiology and chronotherapeutics, Kathmandu University Medical Journal 2004; 2(8): 384-388.
5. Bruguolle B, Lemmer B. Recent advances in chronopharmacokinetics: methodological problems, Life Science 1993; 52: 1809-1824.
6. URL:http://www.uspharmacist.com/oldformat.asp?url=newlook/files/Feat/ACF2F15.cfm&pub_id, accesed on 15/9/10.
7. Botti B, Youan C. Chronopharmaceutics: Gimmick or clinically relevant approach to drug delivery. Journal of Control Release 2004: 337-353.
8. Kowanko IC, Pownall R, Knapp MS. Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of the day. British J Clin Pharma. 1981; 11: 477-84.
9. Kowanko IC, Knapp MS, Pownall R, Swannell AJ. Domiciliary self-measurements of in rheumatoid and the demonstration of circadian rhythmicity. Annuals of the Rheumatic Diseases 1982; 41: 453- 455.
10. Swannell AJ. Biological rhythms and their effect in the assessment of disease activity in rheumatoid arthritis. British J Clin Practice 1983; 38(33): 16- 19.
11. Harkness JAL, Richter MB, Panayi GS. Circadian variation in disease activity in rheumatoid arthritis. British Medical J. 1982; 284: 551-554.
12. Huskisson EC and GP Velo ed. Chronopharmacology of anti-rheumatic drugs with special reference to indomethacin in: Inflammatory Arthropathies. Excepta Medica 1976: 99-105.
13. Javed Qureshi , Alka Ahuja, Sanjula Baboota, Krishna Chutani, Sanyog Jain, Javed Ali, Development and evaluation of a time-specific pulsatile-release tablet of aceclofenac: a solution for morning pain in rheumatoid arthritis, Exp Clin Pharmacol. Jan-Feb 2009; 31(1):15-23.
14. Raghavendra K, Marina Koland, An In-Vivo Evaluation of Chronotherapeutical Drug Delivery System for the Treatment of Hypertension, Saudi Journal of Medical and Pharmaceutical Sciences, Vol-3, Iss-6B (Jun, 2017):643-647.
15. S. Mohan, N. Srinivasarao, K. Lakshmi, Development and Validation of a Stability indicating Related Substances of Baricitinib by RP-HPLC and its Degradation, International Journal of Management and Humanities (IJMH), Volume-4 Issue-2, October 2019, 1-9.